CompletedEUCTR 2018-002901-68

Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responde...

This historical record does not confirm current site availability.

Historical research recordFranceDepression

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: France
Study phase: Phase 2

Get this study by email

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: Not clearly listed
Sponsor: MAPREG
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: France
Age range: Not clearly listed
Official registry ID: EUCTR 2018-002901-68
Official title: Show the full official title
Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responde...

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

France

Registry details

Historical country statuses

France — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is MAPREG.

Want to explore more studies?

Explore studies